In our study, ZBTB4 was remarkably correlated with TMB and MSI in pan-cancer, and we can speculate that ZBTB4 is a powerful biomarker for predicting response to cancer immune checkpoint inhibitor blockade therapy. Here, ZBTB4 is linked to cancer.